Back to results
US 10,703,790 B2Granted
Glycosaminoglycan-antagonising fusion proteins
AssigneeAntagonis Biotherapeutics GmbH
InventorAndreas Kungl
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel monomeric fusion proteins derived from human GAG binding proteins such as chemokines with increased glycosaminoglycan (GAG) binding affinity and knocked-out or reduced GPCR activity compared to wild type GAG binding proteins, which are highly selectively competitive and are of increased bioavailability, and to their use for prevention or treatment of pathological cell movement as in metastasis.
Claims2
A glycosaminoglycan (GAG) binding monomeric fusion protein comprising:
- a. a GAG binding protein moiety,
- b. a human serum albumin (HSA) moiety, and
- c. a linker between said HSA moiety and said GAG binding protein moiety, wherein the fusion protein has the sequence of SEQ ID NO:8.
Dependencies are inferred from the claim text.